Zurich Cantonal Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$168M Buy
377,013
+23,525
+7% +$11M 0.37% 40
2025
Q4
$160M Sell
353,488
-34,823
-9% -$15M 0.35% 38
2025
Q3
$152M Sell
388,311
-6,060
-2% -$2.53M 0.35% 44
2025
Q2
$176M Buy
394,371
+9,661
+3% +$4.45M 0.43% 35
2025
Q1
$187M Buy
384,710
+35,233
+10% +$16.4M 0.54% 26
2024
Q4
$141M Buy
349,477
+29,333
+9% +$13.6M 0.4% 30
2024
Q3
$149M Sell
320,144
-68,702
-18% -$33M 0.44% 34
2024
Q2
$182M Sell
388,846
-45,488
-10% -$19.7M 0.59% 20
2024
Q1
$182M Sell
434,334
-10,853
-2% -$4.59M 0.64% 22
2023
Q4
$181M Buy
445,187
+18,186
+4% +$6.72M 0.69% 21
2023
Q3
$148M Buy
427,001
+5,514
+1% +$1.93M 0.66% 21
2023
Q2
$148M Buy
421,487
+26,496
+7% +$8.93M 0.65% 22
2023
Q1
$124M Buy
394,991
+10,120
+3% +$3.04M 0.61% 25
2022
Q4
$111M Sell
384,871
-9,688
-2% -$2.95M 0.59% 28
2022
Q3
$114M Buy
394,559
+33,449
+9% +$9.62M 0.68% 22
2022
Q2
$102M Buy
361,110
+74,543
+26% +$20M 0.6% 24
2022
Q1
$74.8M Buy
286,567
+160,264
+127% +$38M 0.37% 51
2021
Q4
$27.7M Sell
126,303
-19,306
-13% -$3.75M 0.13% 139
2021
Q3
$26.4M Sell
145,609
-3,951
-3% -$771K 0.14% 132
2021
Q2
$30.2M Buy
149,560
+54,229
+57% +$11.3M 0.17% 116
2021
Q1
$20.5M Buy
95,331
+14,395
+18% +$3.16M 0.12% 163
2020
Q4
$19.1M Buy
80,936
+8,950
+12% +$2.05M 0.12% 165
2020
Q3
$19.6M Buy
71,986
+10,418
+17% +$2.87M 0.14% 135
2020
Q2
$17.9M Sell
61,568
-19,210
-24% -$5.21M 0.15% 128
2020
Q1
$19.2M Buy
80,778
+20,199
+33% +$4.63M 0.18% 115
2019
Q4
$13.3M Buy
60,579
+7,604
+14% +$1.54M 0.1% 220
2019
Q3
$8.97M Buy
52,975
+1,296
+3% +$229K 0.08% 293
2019
Q2
$9.48M Sell
51,679
-6,800
-12% -$1.19M 0.08% 274
2019
Q1
$10.8M Buy
58,479
+9,551
+20% +$1.76M 0.1% 242
2018
Q4
$8.11M Sell
48,928
-74,701
-60% -$12.9M 0.08% 270
2018
Q3
$23.8M Sell
123,629
-4,470
-3% -$796K 0.2% 117
2018
Q2
$21.8M Sell
128,099
-3,811
-3% -$591K 0.19% 116
2018
Q1
$21.5M Buy
131,910
+9,887
+8% +$1.61M 0.2% 119
2017
Q4
$18.3M Buy
122,023
+28,496
+30% +$4.22M 0.16% 148
2017
Q3
$14.2M Buy
93,527
+47,134
+102% +$7.09M 0.13% 181
2017
Q2
$5.98M Sell
46,393
-64
-0.1% -$7.7K 0.06% 353
2017
Q1
$5.08M Buy
46,457
+2,659
+6% +$234K 0.05% 393
2016
Q4
$3.23M Sell
43,798
-2,651
-6% -$216K 0.03% 508
2016
Q3
$4.05M Buy
46,449
+17,746
+62% +$1.68M 0.04% 445
2016
Q2
$2.47M Buy
28,703
+7,599
+36% +$657K 0.03% 480
2016
Q1
$1.68M Hold
21,104
0.02% 588
2015
Q4
$2.66M Buy
21,104
+1,064
+5% +$128K 0.03% 459
2015
Q3
$2.09M Buy
20,040
+1,863
+10% +$239K 0.03% 502
2015
Q2
$2.25M Sell
18,177
-234
-1% -$29.5K 0.03% 491
2015
Q1
$2.17M Buy
18,411
+4,049
+28% +$485K 0.03% 504
2014
Q4
$1.71M Sell
14,362
-1,972
-12% -$222K 0.05% 423
2014
Q3
$1.83M Sell
16,334
-85,733
-84% -$8.16M 0.06% 378
2014
Q2
$9.66M Buy
102,067
+1,445
+1% +$101K 0.28% 81
2014
Q1
$7.12M Buy
100,622
+6,154
+7% +$487K 0.22% 101
2013
Q4
$7.02M Sell
94,468
-10,161
-10% -$708K 0.23% 97
2013
Q3
$7.93M Sell
104,629
-2,638
-2% -$210K 0.27% 82
2013
Q2
$8.57M Buy
+107,267
New +$7.9M 0.3% 76

Other funds holding VRTX

Zurich Cantonal Bank's VRTX Position: Q1 2026 in Review

Zurich Cantonal Bank increased its Vertex Pharmaceuticals (VRTX) stake by 6.7% in Q1 2026, buying an estimated $11M and bringing the position to 377,013 shares worth $168M. The position accounts for 0.37% of the portfolio, ranked #40.

Zurich Cantonal Bank first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $187M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Zurich Cantonal Bank held 377,013 shares of Vertex Pharmaceuticals worth $168M as of Q1 2026.
  • Zurich Cantonal Bank bought 23,525 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11M.
  • Vertex Pharmaceuticals made up 0.37% of Zurich Cantonal Bank's portfolio in Q1 2026, its #40 holding.
  • Zurich Cantonal Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Zurich Cantonal Bank's Vertex Pharmaceuticals position peaked at $187M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.